B6.129-Tnfrsf1btm1Mwm Tnfrsf1atm1Blt/Cnrm

Status

Available to order

EMMA IDEM:02532
International strain nameB6.129-Tnfrsf1btm1Mwm Tnfrsf1atm1Blt/Cnrm
Alternative nameB6.129S-Tnfrsf1aTnfrsf1b
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolTnfrsf1btm1Mwm, Tnfrsf1atm1Blt
Gene/Transgene symbolTnfrsf1b, Tnfrsf1a

Information from provider

ProviderHorst Bluethmann
Provider affiliationPharmaceuticals Divisons, F. Hoffmann-La Roche Ltd.
Genetic informationThe double mutant mice lacking both Tnfrsf1a and Tnfrsf1b were generated by intercrossing the singly deficient mice. B6.129S-Tnfrsf1atm1Blt: A genomic fragment containing the exons II and III and 5' sequences from exon IV of the Tnfrsf1a gene was replaced by a neomycin resistance gene flanked by phosphoglycerate kinase-1 (pgk-1) promoter- and poly (A)+ signal sequences. The insertion of the neo cassette resulted in the introduction of new BglII and StuI sites which were used to confirm the targeting event. The Tnfrsf1a homologies provided at both sides of the neo cassette were 868 bp and ~ 5 kb, respectively. The targeting vector was linearized with XbaI before electroporation into E14 embryonic stem cells derived from 129/Sv mice. B6.129S-Tnfrsf1btm1Mwm: A neomycin resistance gene under the control phosphoglycerate kinase-1 (pgk-1) promoter was inserted into the BstBII site in the second exon, which contains the signal peptide region of TNFR2.
Phenotypic informationB6.129S-Tnfrsf1atm1Blt: Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes (PMID: 8395024) B6.129S-Tnfrsf1btm1Mwm: Mice deficient for Tnfrsf1b show decreased T cell proliferation, decreased interferon-gamma secretion, and decreased interleukin-2 secretion (PMID: 7990930).
Breeding historyThe single deficient strains were backcrossed each to C57BL/6 for 6 generations, then intercrossed.
References
  • Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes.;Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Köntgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H, ;1993;Nature;364;798-802; 8395024
  • Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice.;Erickson S L, de Sauvage F J, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan K C, Schreiber R D, Goeddel D V, Moore M W, ;1994;Nature;372;560-3; 7990930
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredyes
Immunocompromisedyes

Information from EMMA

Archiving centreCNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

IMPC phenotypes (gene matching)
  • abnormal skin morphology / IMPC
  • increased large unstained cell number / IMPC
  • increased grip strength / IMPC
  • increased basophil cell number / IMPC
  • increased neutrophil cell number / IMPC
  • increased eosinophil cell number / IMPC
  • increased NK cell number / IMPC
  • decreased T cell number / IMPC
  • increased B cell number / IMPC
  • abnormal cholesterol homeostasis / IMPC
  • decreased circulating calcium level / IMPC
  • increased lymphocyte cell number / IMPC
  • increased effector memory CD8-positive, alpha-beta T cell number / IMPC
  • increased circulating aspartate transaminase level / IMPC
  • enlarged heart / IMPC
  • decreased locomotor activity / IMPC
  • increased leukocyte cell number / IMPC
  • decreased monocyte cell number / IMPC
  • decreased prepulse inhibition / IMPC
  • abnormal heart morphology / IMPC
  • increased circulating total protein level / IMPC
  • decreased neutrophil cell number / IMPC
MGI phenotypes (allele matching)
  • abnormal response/metabolism to endogenous compounds / MGI
  • decreased circulating interleukin-6 level / MGI
  • decreased sensitivity to induced morbidity/mortality / MGI
  • decreased physiological sensitivity to xenobiotic / MGI
  • decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • abnormal sleep pattern / MGI
  • impaired central nervous system regeneration / MGI
  • increased sensitivity to induced cell death / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • impaired humoral immune response / MGI
  • decreased susceptibility to bacterial infection / MGI
  • decreased circulating alanine transaminase level / MGI
  • abnormal Peyer's patch morphology / MGI
  • abnormal immune system physiology / MGI
  • abnormal lymph node B cell domain morphology / MGI
  • abnormal Peyer's patch follicle morphology / MGI
  • increased susceptibility to bacterial infection / MGI
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • increased susceptibility to parasitic infection / MGI
  • increased susceptibility to type I hypersensitivity reaction / MGI
  • decreased Peyer's patch number / MGI
  • absent follicular dendritic cells / MGI
  • decreased IgG1 level / MGI
  • decreased interleukin-6 secretion / MGI
  • decreased T cell proliferation / MGI
  • decreased interferon-gamma secretion / MGI
  • decreased interleukin-2 secretion / MGI
  • increased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • periinsulitis / MGI
MGI phenotypes (gene matching)
  • increased bone mineral density / MGI
  • abnormal Peyer's patch morphology / MGI
  • abnormal sleep pattern / MGI
  • abnormal immune system physiology / MGI
  • decreased IgG level / MGI
  • liver inflammation / MGI
  • lung inflammation / MGI
  • decreased inflammatory response / MGI
  • increased skin papilloma incidence / MGI
  • decreased tumor incidence / MGI
  • abnormal respiratory mechanics / MGI
  • abnormal airway responsiveness / MGI
  • abnormal lymph node B cell domain morphology / MGI
  • abnormal spleen germinal center morphology / MGI
  • abnormal Peyer's patch follicle morphology / MGI
  • decreased susceptibility to bacterial infection / MGI
  • increased susceptibility to bacterial infection / MGI
  • abnormal macrophage physiology / MGI
  • granulomatous inflammation / MGI
  • impaired skin barrier function / MGI
  • abnormal glutamate-mediated receptor currents / MGI
  • decreased circulating alanine transaminase level / MGI
  • abnormal cytokine secretion / MGI
  • no phenotypic analysis / MGI
  • abnormal nervous system physiology / MGI
  • abnormal response/metabolism to endogenous compounds / MGI
  • increased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • increased susceptibility to parasitic infection / MGI
  • increased susceptibility to type I hypersensitivity reaction / MGI
  • decreased Peyer's patch number / MGI
  • abnormal follicular dendritic cell morphology / MGI
  • absent follicular dendritic cells / MGI
  • decreased IgG1 level / MGI
  • increased circulating tumor necrosis factor level / MGI
  • decreased circulating interleukin-6 level / MGI
  • decreased circulating interleukin-1 beta level / MGI
  • increased interleukin-6 secretion / MGI
  • decreased interleukin-6 secretion / MGI
  • abnormal chemokine secretion / MGI
  • decreased susceptibility to endotoxin shock / MGI
  • increased susceptibility to endotoxin shock / MGI
  • decreased physiological sensitivity to xenobiotic / MGI
  • increased sensitivity to induced cell death / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • decreased sensitivity to induced morbidity/mortality / MGI
  • decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • abnormal neuron proliferation / MGI
  • abnormal oval cell physiology / MGI
  • tumor regression / MGI
  • impaired adaptive thermogenesis / MGI
  • decreased susceptibility to dopaminergic neuron neurotoxicity / MGI
  • decreased microglial cell number / MGI
  • impaired humoral immune response / MGI
  • impaired central nervous system regeneration / MGI
  • abnormal sleep pattern / MGI
  • abnormal immune system physiology / MGI
  • increased inflammatory response / MGI
  • lung inflammation / MGI
  • increased skin papilloma incidence / MGI
  • no abnormal phenotype detected / MGI
  • abnormal blood gas level / MGI
  • abnormal lung compliance / MGI
  • decreased susceptibility to bacterial infection / MGI
  • increased susceptibility to bacterial infection / MGI
  • decreased systemic arterial blood pressure / MGI
  • abnormal glutamate-mediated receptor currents / MGI
  • increased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • increased susceptibility to parasitic infection / MGI
  • decreased T cell proliferation / MGI
  • homeostasis/metabolism phenotype / MGI
  • respiratory system phenotype / MGI
  • skeleton phenotype / MGI
  • periinsulitis / MGI
  • increased circulating tumor necrosis factor level / MGI
  • decreased interferon-gamma secretion / MGI
  • decreased interleukin-2 secretion / MGI
  • microgliosis / MGI
  • decreased susceptibility to dopaminergic neuron neurotoxicity / MGI
  • impaired central nervous system regeneration / MGI

Literature references

  • Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes.;Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Köntgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H, ;1993;Nature;364;798-802; 8395024
  • Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice.;Erickson S L, de Sauvage F J, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan K C, Schreiber R D, Goeddel D V, Moore M W, ;1994;Nature;372;560-3; 7990930

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).